

Please try another search
Investing.com - Cidara Therapeutics Inc (NASDAQ: CDTX) reported second quarter EPS of $-0.140, $0.01 worse than the analyst estimate of $-0.130. Revenue for the quarter came in...
Investing.com - Cidara Therapeutics Inc (NASDAQ: CDTX) reported first quarter EPS of $0.030, $0.09 better than the analyst estimate of $-0.060. Revenue for the quarter came in at...
Cidara Therapeutics, Inc. (Nasdaq: NASDAQ:CDTX), a biotechnology company developing therapeutics designed to save lives and improve the standard of care for patients facing serious...
Investors in Cidara Therapeutics, Inc. (NASDAQ:CDTX) need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 20th 2018 $7.50...
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is expected to report third-quarter 2017 results around Nov 8, before market opens. Last quarter, Merrimack missed bottom-line...
Investors are always looking for stocks that are poised to beat at earnings season and Cidara Therapeutics, Inc. (NASDAQ:CDTX) may be one such company. The firm has earnings...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Engulfing Bearish | 1H | Current | |||
Completed Patterns | |||||
Engulfing Bearish | 30 | 1 | Sep 29, 2023 10:00AM | ||
Engulfing Bearish | 1H | 2 | Sep 28, 2023 03:00PM | ||
Three Inside Up | 1W | 3 | Sep 03, 2023 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
AMD | 103.83 | 104.93 | 102.70 | +1.07 | +1.04% | 21.02M | 10:58:44 | ||
Nike | 96.03 | 99.47 | 95.71 | +6.40 | +7.14% | 15.58M | 10:58:19 | ||
Tesla | 253.27 | 254.77 | 248.61 | +6.89 | +2.80% | 49.16M | 10:58:39 | ||
Palantir | 16.11 | 16.81 | 16.01 | +0.34 | +2.14% | 38.19M | 10:58:20 | ||
NVIDIA | 439.03 | 441.44 | 436.48 | +8.14 | +1.89% | 14.55M | 10:58:29 | ||
Micron | 68.38 | 68.73 | 66.42 | +3.18 | +4.88% | 8.04M | 10:58:36 | ||
Meta Platforms | 306.81 | 310.64 | 305.93 | +2.85 | +0.94% | 7.10M | 10:58:29 | ||
Amazon.com | 128.36 | 129.15 | 127.62 | +2.38 | +1.89% | 18.28M | 10:58:26 | ||
Apple | 172.47 | 173.07 | 171.77 | +1.78 | +1.04% | 13.75M | 10:58:28 | ||
Nio A ADR | 8.94 | 9.22 | 8.86 | +0.03 | +0.28% | 18.58M | 10:58:13 |
Cidara Therapeutics, Inc. is a biotechnology company. The Company is focused on the discovery, development and commercialization of therapeutics designed for patients facing serious diseases. The Company's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. The Company’s primary focus is using its Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates (DFCs), for the prevention and treatment of serious diseases. This technology couples’ potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Its advanced DFC program is CD388, a long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review